On -co -Investments开始制造 一种潜在的癌症药物, 向人类试验前进。 Onco-Innovations starts manufacturing a potential cancer drug, advancing toward human trials.

Onco-Novationations Limited已开始与Dalton Pharma Services一起制造一种潜在的癌症治疗方法,一种纳米粒子制成的PNKP抑制剂。 Onco-Innovations Limited has started manufacturing a potential cancer treatment, a nanoparticle-formulated PNKP inhibitor, with Dalton Pharma Services. 这一步骤将技术从早期研究转向临床前期测试,这是临床试验之前的一个重要阶段。 This step moves the technology from early research to preclinical testing, an essential phase before clinical trials. 这些材料将用于临床前研究,并准备将来的监管批准,目的是最终在人体中测试该药物。 The material will be used in preclinical studies and to prepare for future regulatory approvals, with the goal of eventually testing the drug in humans.